KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) EBT Margin (2016 - 2025)

Historic EBT Margin for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 288.22%.

  • Novavax's EBT Margin fell 1434700.0% to 288.22% in Q3 2025 from the same period last year, while for Sep 2025 it was 35.05%, marking a year-over-year increase of 666600.0%. This contributed to the annual value of 25.89% for FY2024, which is 293100.0% up from last year.
  • As of Q3 2025, Novavax's EBT Margin stood at 288.22%, which was down 1434700.0% from 61.4% recorded in Q2 2025.
  • Novavax's 5-year EBT Margin high stood at 77.98% for Q1 2025, and its period low was 373.39% during Q4 2021.
  • Over the past 5 years, Novavax's median EBT Margin value was 70.31% (recorded in 2023), while the average stood at 105.59%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 7167600bps in 2021, then plummeted by -3908800bps in 2023.
  • Quarter analysis of 5 years shows Novavax's EBT Margin stood at 373.39% in 2021, then soared by 86bps to 51.63% in 2022, then decreased by -17bps to 60.65% in 2023, then crashed by -37bps to 83.32% in 2024, then tumbled by -246bps to 288.22% in 2025.
  • Its EBT Margin stands at 288.22% for Q3 2025, versus 61.4% for Q2 2025 and 77.98% for Q1 2025.